Title |
Ethical issues in nanomedicine: Tempest in a teapot?
|
---|---|
Published in |
Medicine, Health Care and Philosophy, August 2016
|
DOI | 10.1007/s11019-016-9720-7 |
Pubmed ID | |
Authors |
Irit Allon, Ahmi Ben-Yehudah, Raz Dekel, Jan-Helge Solbakk, Klaus-Michael Weltring, Gil Siegal |
Abstract |
Nanomedicine offers remarkable options for new therapeutic avenues. As methods in nanomedicine advance, ethical questions conjunctly arise. Nanomedicine is an exceptional niche in several aspects as it reflects risks and uncertainties not encountered in other areas of medical research or practice. Nanomedicine partially overlaps, partially interlocks and partially exceeds other medical disciplines. Some interpreters agree that advances in nanotechnology may pose varied ethical challenges, whilst others argue that these challenges are not new and that nanotechnology basically echoes recurrent bioethical dilemmas. The purpose of this article is to discuss some of the ethical issues related to nanomedicine and to reflect on the question whether nanomedicine generates ethical challenges of new and unique nature. Such a determination should have implications on regulatory processes and professional conducts and protocols in the future. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 50 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 8 | 16% |
Researcher | 7 | 14% |
Student > Master | 7 | 14% |
Student > Ph. D. Student | 5 | 10% |
Professor | 2 | 4% |
Other | 7 | 14% |
Unknown | 14 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 6 | 12% |
Medicine and Dentistry | 5 | 10% |
Chemistry | 5 | 10% |
Arts and Humanities | 3 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
Other | 14 | 28% |
Unknown | 14 | 28% |